-
High MCM10 expression mediates TMZ resistance and promotes the progression of glioma (vol 95, 93, 2025
Author: Tian, Qiusi; Bao, Zhijun; Zhao, Yifei; Zhang, Qun
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-026-04873-1
-
Why are we still using cisplatin? Rationale for the continued use of cisplatin in oncolog
Author: Arakelyan, Jemma; Loong, Herbert; Gale, Robert Peter; Che, Chi-Ming
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-026-04882-0
-
RETRACTION: Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathwa
Author: Xu, Peng; Wang, Handong; Pan, Hao; Chen, Jiakai; Deng, Chulei
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-026-04874-0
-
A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rat
Author: Qin, Shangwei; Zhang, Yu; Duan, John; Kraft, George; Bowen, Joanne
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-026-04875-z
-
KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cance
Author: Liu, Xiaoqin; Chen, Jun; Shen, Xuwei; Li, Lin
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-026-04872-2
-
Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatmen
Author: Fan, Xiaowei; Ye, Haihan; Qian, Wenkang; Li, Tao; Ding, Xianfeng; Fang, Meiyu; Cao, Jun
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-025-04817-1
-
Recent advances in bispecific antibody-drug conjugates for breast cancer therap
Author: Ji, Xuan; Yang, Yalong; Ma, Cong; Huang, Wenqin; Guo, Senyang; Wang, Lingzi; Zheng, Hongmei; Wu, Xinhong
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-025-04863-9
-
Association between modifications in intravenous chemotherapy dose and disease-free survival and related influencing factors in lung cancer patients: a retrospective study based on inverse probability weightin
Author: Huang, Hangxing; Wang, Jun
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2026; Vol. 96, Issue 1, pp. -. DOI: 10.1007/s00280-025-04853-x
